Health care analysis on myocardial revascularization in patients with chronic coronary heart disease (CHD)
- Conditions
- Chronic CHD in the form of a 2- or 3-vessel or main-vessel diseaseI25Chronic ischaemic heart disease
- Registration Number
- DRKS00022175
- Lead Sponsor
- InGef – Institut für angewandte Gesundheitsforschung Berlin GmbH (InGef)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 386
Inclusion Criteria
Patients
(a) with chronic coronary heart disease and
(b) 2- or 3-vessel or main-vessel disease
(c) who are being treated at one of the recruitment sites
(d) with a promptly planned intervention for myocardial revascularization
Exclusion Criteria
missing informed consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Guidelines-compliant therapy in patients with chronic CHD (2- or 3-vessel or main vessel disease) according to NVL cKHK
- Secondary Outcome Measures
Name Time Method Frequency and quality of heart teams; extent of patient participation in the decision making process; importance of clinical parameters in the decision-making process (e.g. syntax scores, iFR, FFR)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie myocardial revascularization in chronic coronary heart disease patients enrolled in DRKS00022175?
How does observational data from DRKS00022175 compare to randomized trials on revascularization outcomes in 2- or 3-vessel CHD?
Which biomarkers correlate with improved prognosis following myocardial revascularization in REVASK trial participants?
What adverse events are associated with revascularization strategies in chronic ischaemic heart disease as reported in DRKS00022175?
Are there novel drug targets or combination therapies emerging from REVASK's analysis of revascularization effectiveness in I25 disease?